Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 19.1.2017 | EN | Official Journal of the European Union | C 18/28 |

---

JUDGMENT OF THE COURT

of 1 February 2016

in Case E-22/15

EFTA Surveillance Authority v The Principality of Liechtenstein

(Failure by an EEA/EFTA State to fulfil its obligations — Failure to implement — Directive 2011/62/EU — Directive 2012/26/EU)

(2017/C 18/12)

In Case E-22/15, EFTA Surveillance Authority v The Principality of Liechtenstein — APPLICATION for a declaration that by failing to adopt the measures necessary to implement the Acts referred to at point 15q of Chapter XIII of Annex II to the Agreement on the European Economic Area (Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products and Directive 2012/26/EU of the European Parliament and of the Council of 25 October 2012 amending Directive 2001/83/EC as regards pharmacovigilance), as adapted to the Agreement by way of Protocol 1 thereto, within the time prescribed, the Principality of Liechtenstein has failed to fulfil its obligations under Article 2 of each Act and under Article 7 of the Agreement, the Court, composed of Carl Baudenbacher, President, Per Christiansen and Páll Hreinsson (Judge-Rapporteur), Judges, gave judgment on 1 February 2016, the operative part of which is as follows:

The Court hereby:

|  |  |
| --- | --- |
| 1. | Declares that, by failing, within the time prescribed, to adopt the measures necessary to implement the Acts referred to at point 15q, ninth and tenth indent, of Chapter XIII of Annex II to the Agreement on the European Economic Area (Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products and Directive 2012/26/EU of the European Parliament and of the Council of 25 October 2012 amending Directive 2001/83/EC as regards pharmacovigilance), as adapted to the Agreement by way of Protocol 1 thereto, the Principality of Liechtenstein has failed to fulfil its obligations under Article 2 of each Act and under Article 7 of the EEA Agreement. |

|  |  |
| --- | --- |
| 2. | Orders the Principality of Liechtenstein to bear the costs of the proceedings. |

---

[Top](#document1)